ArticleBreast cancer research and treatment2025

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.

Kelly E McCann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.